Blood
Articles in this Issue
Detection of minimal residual disease in t-cell acute lymphoblastic leukemia by 16-color full-spectrum flow cytometry
Abstract Objective: To find a strong and applicable panel for T-ALL MRD detection by flow cytometry and find the relation with genetics. Met...
Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma
Abstract Background: Natural killer (NK) cells play a key role in immune surveillance of multiple myeloma (MM), but their function becomes p...
Implementing linkage coordination: Patient experiences in the recruitment and engagement in care to impact practice enhancement (RECIPE) for sickle cell disease study
Abstract Background: Sickle cell disease (SCD) affects roughly 100,000 people in the United States and can result in significant morbidity,...
Improve therapeutic response through inhibition of endosome machinery in multiple myeloma
Abstract With advanced therapies, the 5-year relative survival rate for multiple myeloma (MM) is about 58%, yet 15-20% of patients survive l...
Btkis and DRC show a reduction of infections and need of hospitalization towards BR and other chemo-immunotherapies in waldenstrom macroglobulinemia.
Abstract Infections are a major source of morbidity and mortality in patients with Waldenström Macroglobulinemia (WM). During the last years...
GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)
Abstract Introduction The pathogenesis of multiple myeloma (MM) is critically regulated by IKZF3 and IKZF1, transcription factors involved i...
Subclonal genomic heterogeneity shapes immune crosstalk and clinical outcomes in multiple myeloma
Abstract Introduction: Subclonal diversity in multiple myeloma (MM)—defined by genetically distinct populations of malignant plasma cells—pl...
Real world use of sutimlimab in patients with cold agglutinin disease: An international study
Abstract Sutimlimab has demonstrated high efficacy in increasing hemoglobin levels and reducing markers of hemolysis in patients with cold a...
Trends and disparities in myelodysplastic Syndrome–Associated mortality in the u.S. from 1999 to 2020: A population-based study using the CDC wonder database
Abstract Background: Myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic disorders characterized by ineffective hematopoies...
MRC2: A tumor-restricted surface antigen for immunotherapy in Acute Myeloid Leukemia
Abstract Background: Acute myeloid leukemia (AML) is an aggressive blood cancer with limited treatment options and poor outcomes. Progress in...
Real-world safety and efficacy of BCMA bispecific antibodies in relapsed light chain amyloidosis
Abstract Background: Light Chain (AL) Amyloidosis is a clonal plasma cell and protein processing disorder resulting in misfolded kappa or lam...
Targeting VDAC1 to induce mitochondrial DNA–STING signaling and lysosomal cell death in T-cell lymphoma
Abstract The study investigates the crosstalk between mitochondria and Stimulator of Interferon Genes (STING) signaling in T-cell lymphoma (...
Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy
Abstract Background: Lymphomatous involvement of extranodal (EN) sites has been recognized as a negative prognostic factor for patients (pts...
Platelets stabilize factor VIIIa against loss of activity through subunit dissociation
Abstract Activated platelets have binding sites for factor VIII (FVIII) that include soluble fibrin bound to the αIIbβ3 integrin (Phillips e...
The efficacy of cilta-cel after a prior BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma
Abstract Introduction: BCMA-directed CAR-T cell therapy has demonstrated remarkable efficacy in patients with relapsed/refractory multiple m...
Increasing incidences in primary lung marginal zone lymphoma: A SEER database analysis.
Abstract Primary lung marginal zone lymphoma (MZL) is a rare subtype of extra-nodal MZL. It typically follows an indolent course, with surge...
Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis
Abstract Introduction: Single agents, such as Bruton tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors, are being widely used in the tre...
Real world outcomes analysing the use of glucocorticoids in patients with acute chest syndrome: A propensity score matched analysis from global federated health research network
Abstract Introduction Acute chest syndrome (ACS) is a life-threatening complication of sickle cell disease that often requires hospitalizati...
Beyond the assays: Managing unresolvable TMA and the pharmacokinetic cost of plasma exchange
Abstract Introduction: Thrombotic microangiopathies (TMAs) encompass a spectrum of life-threatening disorders that share overlapping clinica...
The academic center effect: Better outcomes for patients with DLBCL
Abstract Background Approximately 5 per 100,000 people per year will develop Diffuse Large B-Cell Lymphoma (DLBCL) making it the most freque...
Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy
Abstract Chimeric antigen receptor (CAR) T cell therapy has shown considerable potential for treating refractory autoimmune diseases. Howeve...
Preliminary safety and efficacy results of A phase ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML
Abstract Background: Azacitidine combined with venetoclax (AZA+VEN) is the standard of care treatment for older and/or unfit patients (pts)...
Real world outcomes in 355 patients with Acute Myeloid Leukemia arising from chronic myelomonocytic leukemia: A multinational retrospective study
Abstract Background Secondary acute myeloid leukemia (sAML) designates AML arising from prior hematologic disorder or chemo/radiation. sAML c...
Low vitamin d is an unmodifiable adverse prognostic factor in older DLBCL patients: Results from the previd randomized trial by fondazione italiana linfomi (FIL).
Abstract Background: R-CHOP remains the standard of care for fit elderly patients with diffuse large B-cell lymphoma (DLBCL), while modified...
S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in multiple myeloma.
Abstract Background: S100A8/A9 is a calcium-binding alarmin released during cellular stress and inflammation, modulating immune responses. W...